Jump to content

3-Methylphenethylamine

From Wikipedia, the free encyclopedia
(Redirected from 3-methylphenethylamine)

3-Methylphenethylamine
Names
Preferred IUPAC name
2-(3-Methylphenyl)ethan-1-amine
Other names
2-(3-Methylphenyl)ethanamine
3-Methylbenzeneethanamine
2-(m-Tolyl)ethan-1-amine
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.189.789 Edit this at Wikidata
UNII
  • CC1=CC(=CC=C1)CCN
Properties
C9H13N
Molar mass 135.20622
Appearance clear liquid at room temp.
Density 1.0±0.1 g/cm3
Boiling point 110 °C (230 °F; 383 K) / 20 mmHg
240.9519 °C / 760 mmHg Experimental[1]
Hazards
Occupational safety and health (OHS/OSH):
Main hazards
Corrossive
Flash point 90.5 ± 6.3 °C (194.9 ± 11.3 °F; 363.6 ± 6.3 K)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

3-Methylphenethylamine (3MPEA) is an organic compound with the chemical formula of C9H13N. 3MPEA is a human trace amine associated receptor 1 (TAAR1) agonist,[2] a property which it shares with its monomethylated phenethylamine isomers, such as amphetamine (α-methylphenethylamine), β-methylphenethylamine, and N-methylphenethylamine (a trace amine).[2]

Very little data, even on toxicity, is available about its effects on humans other than that it is corrosive and activates the human TAAR1 receptor.[1]

References

[edit]
  1. ^ a b "2-(3-Methylphenyl)ethanamine". Chemspider. Retrieved 30 May 2014.
  2. ^ a b Wainscott DB, Little SP, Yin T, Tu Y, Rocco VP, He JX, Nelson DL (January 2007). "Pharmacologic characterization of the cloned human trace amine-associated receptor1 (TAAR1) and evidence for species differences with the rat TAAR1". The Journal of Pharmacology and Experimental Therapeutics. 320 (1): 475–85. doi:10.1124/jpet.106.112532. PMID 17038507. S2CID 10829497. Several series of substituted phenylethylamines were investigated for activity at the human TAAR1 (Table 2). A surprising finding was the potency of phenylethylamines with substituents at the phenyl C2 position relative to their respective C4-substituted congeners. In each case, except for the hydroxyl substituent, the C2-substituted compound had 8- to 27-fold higher potency than the C4-substituted compound. The C3-substituted compound in each homologous series was typically 2- to 5-fold less potent than the 2-substituted compound, except for the hydroxyl substituent. The most potent of the 2-substituted phenylethylamines was 2-chloro-β-PEA, followed by 2-fluoro-β-PEA, 2-bromo-β-PEA, 2-methoxy-β-PEA, 2-methyl-β-PEA, and then 2-hydroxy-β-PEA.
    The effect of β-carbon substitution on the phenylethylamine side chain was also investigated (Table 3). A β-methyl substituent was well tolerated compared with β-PEA. In fact, S-(−)-β-methyl-β-PEA was as potent as β-PEA at human TAAR1. β-Hydroxyl substitution was, however, not tolerated compared with β-PEA. In both cases of β-substitution, enantiomeric selectivity was demonstrated.
    In contrast to a methyl substitution on the β-carbon, an α-methyl substitution reduced potency by ~10-fold for d-amphetamine and 16-fold for l-amphetamine relative to β-PEA (Table 4). N-Methyl substitution was fairly well tolerated; however, N,N-dimethyl substitution was not.